Healthcare Industry News: cholangiopancreatography
News Release - September 3, 2008
CONMED Launches Multiple New Gastrointestinal Endoscopy ProductsUTICA, N.Y., Sept. 3, 2008 -- (Healthcare Sales & Marketing Network) -- CONMED Corporation's (NasdaqGS:CNMD ) CONMED Endoscopic Technologies business unit today announced receipt of U.S. Food and Drug Administration (FDA) clearance and have begun launch activity for the Axcess(tm) Multidirectional Papillotome, the Gore VIABIL(r) Biliary Endoprosthesis, the Auto-Band Ligator and the Beamer(tm) System and related Beamer(tm) Argon Snare Probe.
Mr. Joseph J. Corasanti, President & Chief Executive Officer summarized, ``In addition to helping CONMED remain at the forefront of innovation for gastrointestinal endoscopy, these new products are expected to drive near-term growth within our Endoscopic Technologies division. We are excited about the ever-expanding role endoscopy continues to play in medicine as a whole, and our ability to contribute to advancements in technology.''
Axcess(tm) Multi-Directional Papillotome
A papillotome is an electrosurgical endoscopic wire-guided catheter used in conjunction with a flexible endoscope to diagnose disease, clear obstructions and restore patency in the biliary tract. Axcess(tm) is the first papillotome to offer physicians incremental, multi-directional tip movement to help them achieve the desired angle of approach and maintain tip position, thus reducing procedure time. With its micro-mobility technology, the Axcess(tm) Multi-Directional Papillotome allows the physician greater flexibility and procedural access to the common bile and pancreatic ducts, providing GI Therapeutic Endoscopists an innovative solution to initial cannulation issues encountered during Endoscopic Retrograde cholangiopancreatography procedures.
Gore VIABIL(r) Biliary Endoprosthesis
When CONMED introduced the Gore VIABIL(r) Biliary Endoprosthesis (covered stent) in 2007, it presented advancements in patency rates, demonstrated minimal migration and unparalleled conformability in tortuous anatomies. This most recent FDA clearance introduces exclusive Pull-Line deployment technology for the VIABIL stent. This groundbreaking delivery system enhances the physician's control and accuracy in biliary stent placement. CONMED Endoscopic Technologies holds the exclusive distribution rights of the Gore VIABIL(r) Biliary Endoprosthesis in the United States and selected international markets.
The Auto-Band Ligator is used to band esophageal varices (dilated veins that bleed) or hemorrhoids in the colon. In a band ligation procedure, a small band is deployed to the base of the bleeding site or hemorrhoid stopping the blood flow. This ligation procedure is an alternative to invasive surgery to achieve endoscopic hemostasis. The Auto-Band Ligator controls positioning, ensuring only one band is deployed at a time.
Beamer(tm) System and Beamer(tm) Argon Snare Probes
This proprietary electrosurgical platform utilizes radio frequency electrical energy to ionize a stream of argon gas, which efficiently and rapidly causes hemostasis and resection of lesions during gastroenterology and bronchoscopy procedures. The CONMED Beamer(tm) System and Beamer(tm) Argon Snare Probes offer ease of use, control, and multiple therapies in one complete system. This new platform includes a snare and an argon probe in one convenient catheter that snares, resects and beams polyps and lesions with just a single probe. Multiple clinical studies have shown an added benefit in preventing lesion recurrence at the procedure site if argon therapy is used. The Beamer(tm) system and Snare Probes could have a significant impact on electrosurgery for GI and Pulmonary Endoscopy for the treatment of bleeding and the resection of lesions.
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. Headquartered in Utica, New York, the Company's 3,200 employees distribute its products worldwide from several manufacturing locations.
Forward Looking Information
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company's ability to devise and execute strategies to respond to market conditions.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.